NCT00113347 - Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Head and Neck Cancer

Interventions

DRUG

Erlotinib

Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.

DRUG

Docetaxel

15 mg/m\^2 or 20 mg/m\^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.

RADIATION

Radiation Therapy

Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.

Trial Locations (1)

UT MD Anderson Cancer Center, Houston